In tandem, further development and validation of advanced imaging techniques (such as ultra-high-b diffusion MRI or tracer-based MRI of glymphatic flow) might allow clinicians to monitor AQP4 function in vivo during stroke recovery [68,69,70]; these could guide when to switch a therapy from inhibitory to promotive, truly personalizing edema management. This evidence concerns the gene AQP4 and stroke disorder.